Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Probiotix HealthFRA:X90 Receivables Turnover is 2.60 as of Dec. 2025. The stock has 1 warning sign investors should review. Among 840 Biotechnology companies, Probiotix Health ranks better than 65.12% on this metric.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Probiotix Health's Revenue for the
six
months ended in Dec. 2025 was €1.59 Mil. Probiotix Health's average Accounts Receivable for the
six
months ended in Dec. 2025 was €0.61 Mil.
Hence, Probiotix Health's Receivables Turnover for the
six
months ended in Dec. 2025 was 2.60.
Probiotix Health (FRA:X90) Receivables Turnover Explanation
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Probiotix Health Receivables Turnover Related Terms
Probiotix Health Receivables Turnover Historical Data
* Premium members only.
The historical data trend for Probiotix Health's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:X90 vs VRTX, REGN, RVMD: Receivables Turnover Comparison
For the Biotechnology subindustry, Probiotix Health's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Probiotix Health Receivables Turnover vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Probiotix Health's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Probiotix Health's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Probiotix Health (FRA:X90) has a Receivables Turnover of 2.60 as of Dec. 2025. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Probiotix Health and its competitors. According to the industry distribution chart, Probiotix Health ranks #293 out of 840 companies in the Biotechnology industry, placing it in the top 34.9%.
Is Probiotix Health's Receivables Turnover too high?
Probiotix Health's current Receivables Turnover is 2.60. The Biotechnology industry median Receivables Turnover is 5.28. Probiotix Health's value of 2.60 is 50.7% below this industry median. Based on the distribution chart, Probiotix Health ranks #293 out of 840 companies in the Biotechnology industry, which is above the industry midpoint.
How does Probiotix Health's Receivables Turnover compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Probiotix Health ranks #293 out of 840 companies for Receivables Turnover. This puts Probiotix Health in the upper half of its industry. The industry median Receivables Turnover is 5.28. Probiotix Health's value of 2.60 is 50.7% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Biotechnology company?
The median Receivables Turnover among Biotechnology companies is 5.28, based on 840 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Probiotix Health's current Receivables Turnover of 2.60 is 50.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Probiotix Health and its competitors. For the Biotechnology industry, the median Receivables Turnover is 5.28 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Probiotix Health's current Receivables Turnover is 2.60. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Probiotix Health stock overvalued right now?
Probiotix Health (FRA:X90) has a current Receivables Turnover of 2.60. The stock's GF Value™ is €0.08, compared to a current price of €0.07 — trading 13.1% below its estimated fair value. The current Receivables Turnover is 2.60 and 50.7% below the Biotechnology industry median of 5.28. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Probiotix Health (FRA:X90), the current Receivables Turnover is 2.60 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Probiotix Health PLC is a life sciences company that develops probiotics to tackle cardiovascular disease and other lifestyle conditions that are affecting growing numbers of people across the world. The company has one class of business, in three geographical areas, being that of identifying and developing microbial strains, compounds and formulations for use in the nutraceutical industry. Its geographical segments include the United Kingdom, the United States, and the Rest of the World. It generates the majority of its revenue from the United States.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:X90 has been successfully added to your 
